Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
US Department of Justice
Merck
QuintilesIMS
Colorcon
Cipla
UBS
Chubb

Generated: April 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,774,104

« Back to Dashboard

Summary for Patent: 6,774,104
Title: Stabilized pharmaceutical composition in lyophilized form
Abstract:A stabilized pharmaceutical composition in lyophilized form comprising: a cyclic polypeptide compound represented by the general formula (I): ##STR1## wherein R.sup.1 is a hydrogen atom or an acyl group and R.sup.2 and R.sup.3 are, the same or different, a hydrogen atom or a hydroxyl group, or a salt thereof and the stabilizer.
Inventor(s): Sawai; Seiji (Hyogo, JP), Kasai; Akihiro (Nara, JP), Otomo; Kazumi (Osaka, JP)
Assignee: Fujisawa Pharmaceutical Co., Ltd. (Osaka, JP)
Application Number:09/786,125
Patent Claim Types:
see list of patent claims
Composition; Compound; Formulation; Use;

Drugs Protected by US Patent 6,774,104

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astellas MYCAMINE micafungin sodium INJECTABLE;IV (INFUSION) 021506-002 Mar 16, 2005 RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES ➤ Sign Up
Astellas MYCAMINE micafungin sodium INJECTABLE;IV (INFUSION) 021506-002 Mar 16, 2005 RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS ➤ Sign Up
Astellas MYCAMINE micafungin sodium INJECTABLE;IV (INFUSION) 021506-003 Jun 27, 2006 RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES ➤ Sign Up
Astellas MYCAMINE micafungin sodium INJECTABLE;IV (INFUSION) 021506-003 Jun 27, 2006 RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,774,104

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan11/187713Jul 01, 1999
PCT Information
PCT FiledJune 29, 2000PCT Application Number:PCT/JP00/04381
PCT Publication Date:January 11, 2001PCT Publication Number: WO01/02002

Non-Orange Book US Patents Family Members for Patent 6,774,104

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,112,565 Stabilized pharmaceutical composition in lyophilized form ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Daiichi Sankyo
Argus Health
Chinese Patent Office
Mallinckrodt
Express Scripts
Deloitte
Moodys
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.